Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

UBS Maintains Buy on Acumen Pharmaceuticals, Lowers Price Target to $6

Author: Benzinga Newsdesk | August 15, 2024 09:11am

UBS analyst Colin Bristow maintains Acumen Pharmaceuticals (NASDAQ:ABOS) with a Buy and lowers the price target from $14 to $6.

Posted In: ABOS